Hims & Hers Shares Plunge After FDA Panel’s First ‘No’ on a Popular Peptide
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
/ 220 items
#andre↓
FDA Approves Lytenava: First Official Eye-Only Version of Bevacizumab for Wet AMD
Purpose-built for the eye, it ends years of off-label repackaging.
Lilly’s Next Obesity Blockbuster Retatrutide on Track for 2027 Approval After Five Positive Phase 3 Studies
Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.
FDA Clears MannKind’s Furoscix ReadyFlow — Company Raises $50M to Cover Milestone Payment
Following FDA clearance of Furoscix ReadyFlow for heart failure and CKD edema, MannKind secures $50 million to fund the $45M milestone payment.
Zevra Therapeutics Shares Plunge After EU Rejects Arimoclomol for Rare Disease
Company plans to request re-examination.
Wise’s US Banking Ambitions Hit Roadblock as OCC Rejects Application
Wise shares drop after OCC rejects its US national trust bank application over compliance issues and policy changes. Firm plans new GENIUS Act bid.